Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655476 | 1.00 | REN (0.47) | REN | |
| SCHEMBL4531133 | 0.87 | REN (0.47) | REN | |
| SCHEMBL9948074 | 0.87 | REN (0.47) | REN | |
| SCHEMBL15908018 | 0.83 | REN (0.47) | REN | |
| SCHEMBL16369589 | 0.83 | REN (0.47) | REN | |
| SCHEMBL22045827 | 0.83 | REN (0.47) | REN | |
| SCHEMBL14655570 | 0.82 | REN (0.48) | REN | |
| SCHEMBL12503115 | 0.82 | REN (0.48) | REN | |
| SCHEMBL4048454 | 0.82 | REN (0.48) | REN | |
| SCHEMBL9928632 | 0.82 | REN (0.47) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345677-B2 | Compositions, methods and kits relating to HER-2 cleavage | INCYTE CORPORATION (US) | 2016-05-24 | — | — | US | claimed |
| US-9067868-B2 | Chemical process for opening ring compounds | CHEMO IBERICA, S.A. (ES) | 2015-06-30 | — | — | US | claimed |
| US-20140213821-A1 | CHEMICAL PROCESS FOR OPENING RING COMPOUNDS | CHEMO IBERICA, S. A. (ES) | 2014-07-31 | — | — | US | claimed |
| EP-2736875-A1 | CHEMICAL PROCESS FOR OPENING RING COMPOUNDS | Chemo Ibérica, S.A. (ES) | 2014-06-04 | — | — | EP | claimed |
| WO-2013014191-A1 | CHEMICAL PROCESS FOR OPENING RING COMPOUNDS | CHEMO IBERICA, S. A. (ES) | 2013-01-31 | — | — | WO | claimed |
| EP-2551260-A1 | Chemical process for opening ring compounds | Chemo Ibérica, S.A. (ES) | 2013-01-30 | — | — | EP | claimed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| EP-2576500-A2 | PROCESS FOR PRODUCING ALISKIREN | Chemo Iberica, S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| US-20130071899-A1 | Process for Producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2013-03-21 | — | — | US | disclosed |
| WO-2011151442-A2 | PROCESS FOR PRODUCING ALISKIREN | CHEMO IBERICA, S.A. (ES) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213821-A1 | CHEMICAL PROCESS FOR OPENING RING COMPOUNDS | LSS, CILK1, DCXR | REN 2429/4885 |
| US-20130071899-A1 | Process for Producing Aliskiren | REN, AGTR1, AGTR2 | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.